Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14599759 | 0.99 | KMT2A (0.55) | KMT2APTPN1CAPN1CAPN2 | |
| SCHEMBL5557617 | 0.99 | KMT2A (0.55) | KMT2APTPN1CAPN1CAPN2 | |
| SCHEMBL5555625 | 0.92 | KMT2A (0.60) | KMT2APTPN1CAPN1CAPN2 | |
| SCHEMBL5555621 | 0.88 | CAPN1 (0.47) | KMT2APTPN1CAPN1CAPN2 | |
| SCHEMBL5556637 | 0.87 | KMT2A (0.54) | KMT2ACAPN1CAPN2 | |
| SCHEMBL4413564 | 0.85 | KMT2A (0.52) | KMT2APTPN1CAPN1CAPN2 | |
| SCHEMBL14599734 | 0.83 | CAPN1 (0.50) | KMT2APTPN1CAPN1CAPN2 | |
| SCHEMBL5555998 | 0.82 | KMT2A (0.58) | KMT2ACAPN1CAPN2 | |
| SCHEMBL5555530 | 0.81 | KMT2A (0.54) | KMT2APTPN1CAPN1CAPN2 | |
| SCHEMBL14599747 | 0.81 | KMT2A (0.54) | KMT2APTPN1CAPN1CAPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | CA14, CA13, CA1 | KMT2A 2223/4885PTPN1 3477/4885CAPN1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.